Please assess the completion status of the following clinical trial:

Trial Title: Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Is within the age limits and has signed informed consent~* Weighs at least 50 kg~* Had a previous diagnosis of ACS (UA, STEMI, or NSTEMI), underwent PCI, and received one of the following treatments:~  * Clopidogrel MD of 75 mg and aspirin 81-100 mg for 2-8 weeks following clopidogrel loading dose (LD) of 300 mg or 600 mg at the time of PCI~ * Ticagrelor MD of 90 mg twice daily (BID) and aspirin 81-100 mg for 1-4 weeks and switching to clopidogrel MD of 75 mg and aspirin 81-100 mg for 2-4 weeks following ticagrelor LD of 180 mg at the time of PCI~ * Clopidogrel MD 75 mg and aspirin 81-100 mg for 2-8 weeks following ticagrelor LD of 180 mg at the time of PCI~ * Or based on investigator's judgment with at least 2 weeks continued use of clopidogrel MD and aspirin 81-100 mg per day before switching to prasugrel and maximum 8 weeks P2Y12 inhibitors MD treatment (prasugrel is not allowed)~* Is willing and able to abide by the rules of the research unit and study restrictions~* If a woman of child-bearing potential, has a negative serum pregnancy test at screening~* Agrees to use at least one method of contraception during the study~Exclusion Criteria:~* Has active bleeding, significant risk of hemorrhage, or unusual susceptibility to bleed~* Had previous hemorrhagic stroke at any time, or transient ischemic attack (TIA) or ischemic stroke within 3 months before the informed consent date~* Has known allergies or hypersensitivity to prasugrel, aspirin, or any of their excipients~* Has significant hypertension at screening or baseline assessment~* Has hemoglobin levels \<10.5 g/dL or hematocrit levels \<30%~* Has severe left ventricular systolic dysfunction, ejection fraction \<30%~* Is currently undergoing hemodialysis~* Has evidence of severe hepatic disease or any of the following: serum alanine transaminase or aspartate transaminase ≥3 times the upper limit of normal (ULN); or bilirubin ≥2 times the ULN at screening~* Has any clinical laboratory result performed at screening that is determined to be detrimental to the patient or could compromise the study as determined the Investigator~* Has previously participated in this study or in another interventional trial that is not compatible with this study~* Has evidence of significant active neuropsychiatric disease, alcohol abuse or drug abuse as determined by the Investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): Participants with ACS who underwent PCI, and were previously taking clopidogrel, receive a maintenance dose (MD) of prasugrel for a total of 28 weeks (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)

Based on this trial design, predict the completion outcome and termination type (if applicable).